Autonomix Medical to Present at LSI USA ’26
Autonomix Medical (NASDAQ: AMIX) announced that Brad Hauser, President and CEO, will present at LSI USA ’26 on March 17, 2026 at 9:15 AM PT.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Autonomix Medical (NASDAQ: AMIX) announced that Brad Hauser, President and CEO, will present at LSI USA ’26 on March 17, 2026 at 9:15 AM PT. Management will be available for in-person one-on-one meetings with registered, qualified investors attending the conference.
The presentation is accessible to registered attendees only. LSI USA '26 is a global medtech summit for executives, investors and innovators featuring keynote sessions, panels and startup presentations.
Details
News Market Reaction – AMIX
On Mar 11, the day this news came out, AMIX closed 0.25% above the previous close.
Data tracked by StockTitan Argus for the Mar 11 session.
Key Figures
- Net loss
- $14.0 million
- Nine months ended Dec 31, 2025 (10-Q filed Feb 11, 2026)
- Cash balance
- $9.9 million
- As of Dec 31, 2025 (10-Q filed Feb 11, 2026)
- Cash used in operations
- $9.4 million
- Nine months ended Dec 31, 2025 (10-Q filed Feb 11, 2026)
- Funding needed
- $30–$36 million
- Estimated additional financing to reach first commercialization (10-Q Feb 11, 2026)
- Nasdaq bid minimum
- $1.00 per share
- Minimum bid requirement cited in Jan 16, 2026 Nasdaq deficiency 8-K
- Equity purchase facility
- $15.0 million
- Lincoln Park equity purchase agreement disclosed Nov 12, 2025 10-Q
- Warrant proceeds potential
- $7.7 million
- Maximum gross proceeds if all Common Warrants exercised in cash (S-3 / 424B3)
- PIPE gross proceeds
- $5.0 million
- November 2025 private placement described in Nov 19, 2025 8-K and S-3
Historical Context
-
Selection for CRT 2026 Best Innovation oral presentation highlighting core technology.
-
Top Abstract podium selection for novel transvascular RF peripheral nerve neurolysis data.
-
CEO Corner segment detailing publication strategy and scientific validation efforts.
-
Announcement of new long-term pain mitigation data in pancreatic cancer at SSO 2026.
-
Final RF ablation pain mitigation data to be presented at SIO 2026 ePoster session.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
THE WOODLANDS, TX, March 11, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that Brad Hauser, President and Chief Executive Officer of Autonomix will present at LSI USA ’26 on Tuesday, March 17, 2026 at 9:15 AM PT.
In addition to the presentation, management will be available to participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the conference.
The in-person presentation will be accessible to those registered to attend the event. For more information, please visit the conference website.
LSI USA '26, organized by Life Science Intelligence, is a leading global medtech summit that convenes executives, investors and innovators from across the healthcare industry. The event features keynote sessions, expert panels and startup presentations focused on advancing medical technology, fostering partnerships and accelerating innovation across the life sciences sector.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Forward Looking Statements
Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Such forward-looking statements can be identified by the use of words such as “should,” “might,” “may,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “forecasts,” “expects,” “plans,” and “proposes.” Forward-looking statements in this press release include expectations regarding the potential effectiveness and clinical benefits of Autonomix's nerve-targeted treatments for pancreatic cancer pain and other conditions.
Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on May 29, 2025, and from time to time, our other filings with the SEC. Forward-looking statements speak only as of the date of this press release and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.
Investor and Media Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
autonomix@jtcir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.